Description
Product details
GLISITAPTIN M 50/500 Sitagliptin Phosphate (50mg) & Metformin HCI (500mg) Introduction to GLISITAPTIN M 50/500 GLISITAPTIN M 50/500 is an advanced medication designed for the treatment of type 2 diabetes. This combination therapy brings together two potent active ingredients, Sitagliptin Phosphate and Metformin Hydrochloride (HCI), each playing a pivotal role in managing blood sugar levels effectively. This article explores the benefits, mode of action, and essential considerations associated with GLISITAPTIN M 50/500, catering to patients who require a comprehensive approach to diabetes management. The Components of GLISITAPTIN M 50/500 1. Sitagliptin Phosphate (50mg): Sitagliptin Phosphate is a member of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It works by enhancing the body's ability to maintain higher levels of incretin hormones when needed. Incretins help to increase insulin release, especially after a meal, and decrease the amount of sugar made by the liver. The inclusion of 50mg of Sitagliptin in GLISITAPTIN M 50/500 helps in stabilizing post-prandial blood glucose levels. 2. Metformin HCI (500mg): Metformin HCI is one of the most extensively studied diabetes drugs. It primarily works by reducing the production of glucose in the liver, improving the sensitivity of muscle cells to insulin, and therefore helping glucose to enter the cells more effectively. Metformin also has benefits in terms of weight management, making it a valuable component for many diabetics who are also dealing with overweight or obesity issues. Benefits of GLISITAPTIN M 50/500 GLISITAPTIN M 50/500 offers several advantages for managing type 2 diabetes. The combination of Sitagliptin and Metformin HCI targets different aspects of diabetes management: Enhanced Glycemic Control: Together, these medications help to improve blood sugar control more effectively than either component alone, reducing both fasting and postprandial glucose levels. Weight Neutral: Unlike some other diabetes medications, Sitagliptin is weight-neutral, meaning it does not contribute to weight gain, which is an essential factor for many patients. Reduced Risk of Hypoglycemia: Sitagliptin, as part of this combination, contributes to a lower risk of hypoglycemia compared to some other therapies, particularly when used without concurrent sulfonylureas. Improved Insulin Sensitivity: Metformin enhances the body’s sensitivity to insulin, helping to lower blood glucose levels more efficiently. Important Considerations While GLISITAPTIN M 50/500 is highly effective for many individuals, it is not suitable for everyone. Patients with kidney issues or severe heart failure should discuss the risks with their healthcare provider, as Metformin has specific contraindications related to renal function. Additionally, potential side effects such as gastrointestinal upset from Metformin or the rare risk of pancreatitis from Sitagliptin require careful monitoring. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 BUY NOW https://www.sterisonline.com/product/glisitaptin-m-50-500-133906
